Amedisys, Inc. (NASDAQ:AMED) Q3 2022 Earnings Conference Call October 27, 2022 11:00 AM ET
Company Participants
Nick Muscato – Chief Strategy Officer
Chris Gerard – President and Chief Executive Officer
Scott Ginn – Executive Vice President and Chief Financial Officer
Conference Call Participants
Brian Tanquilut – Jefferies
Matt Larew – William Blair
Justin Bowers – Deutsche Bank
A.J. Rice – Credit Suisse
Sarah James – Barclays
Ben Hendrix – RBC Capital Markets
Bill Sutherland – Benchmark Company
John Ransom – Raymond James
Scott Fidel – Stephens
Whit Mayo – SVB Securities
Tao Qiu – Stifel
Andrew Mok – UBS
Joanna Gajuk – Bank of America
Operator
Greetings. Welcome to the Amedisys Third Quarter 2022 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that today's conference is being recorded.
At this time, I'll turn the conference over to Nick Muscato, Chief Strategy Officer. Nick, you may now begin. And Nick, please go ahead. Mr. Muscato, you may begin your presentation. Ladies and gentlemen, please standby for one moment. We're experiencing technical difficulties. Mr. Muscato, please go ahead. One moment, we'll get that taken care of. Once again, Mr. Muscato, we'll be good now.
Nick Muscato
Thank you, operator, and welcome to the Amedisys investor conference call to discuss the results of our third quarter ended September 30, 2022. A copy of our press release, supplemental slides and related Form 8-K filing with the SEC are available on the Investor Relations page on our website. Speaking on today's call from Amedisys will be President and Chief Executive Officer, Chris Gerard; and Executive Vice President and Chief Financial Officer, Scott Ginn.
Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Amedisys today. The company assumes no obligation to update information provided on this call to reflect subsequent events other than as required under applicable securities laws. These forward-looking statements may involve a number of risks and uncertainties, which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties, including factors detailed in our SEC filings, including our Form 10-K, 10-Q and 8-K. In addition, as required under SEC Regulation G, a reconciliation of any non-GAAP measure mentioned during our call today to the most comparable GAAP measure will be available in our Forms 10-Q, 10-K and 8-K.